光动力疗法联合拉帕替尼抑制人表皮生长因子受体-2阳性乳腺癌细胞的基础研究

doi:10.12114/j.issn.1007-9572.2019.00.165

摘要/Abstract

摘要： 背景　光动力疗法（PDT）对增生性疾病有很好的治疗效果，其在抗肿瘤治疗中表现出高效、毒副作用小等优点。拉帕替尼（LAP）是一种口服片剂，主要作用于表皮生长因子受体-1（HER1）和表皮生长因子受体-2（HER2），属于双靶点受体酪氨酸激酶抑制剂。然而目前PDT与LAP联用的协同效应还不是很明确。目的　探讨新型光敏剂5-氨基乙酰丙酸（5-ALA）用于PDT对人HER2阳性乳腺癌细胞系SKBR3的抑制情况，并分析其具体机制，同时讨论PDT联合LAP对HER2阳性乳腺癌的治疗效果，以期为HER2阳性乳腺癌的治疗提供实验依据，为相关研究提供参考。方法　本研究时间为2016年5月—2017年12月。将对数生长期的HER2阳性乳腺癌细胞系SKBR3随机分为空白对照组（不做干预）、LAP组〔分别加入不同浓度梯度（0.50、1.00、2.00、5.00、10.00 μmol/L）的LAP〕、PDT组〔分别加入不同浓度梯度（0.25、0.50、1.00、2.00、4.00 mmol/L）的5-ALA，后给予激光照射〕、LAP+PDT组〔分别加入不同浓度梯度（0.50、1.00、2.00、5.00、10.00 μmol/L）的LAP，再加入不同浓度梯度（0.25、0.50、1.00、2.00、4.00 mmol/L）的5-ALA，后给予激光照射〕，分别计算LAP和5-ALA的半数抑制浓度（IC50），确定最佳给药浓度及后续研究LAP组、PDT组、LAP+PDT组给药浓度，分别比较各组在最佳给药浓度下24、48 h时的细胞生长抑制率。将对数生长期的HER2阳性乳腺癌细胞系SKBR3随机分为空白对照组（不做干预）、LAP组（加入1.00 μmol/L的LAP）、PDT组（加入1.00 mmol/L的5-ALA，后给予激光照射）、LAP+PDT组（加入1.00 μmol/L的LAP，再加1.00 mmol/L的5-ALA，后给予激光照射），采用流式细胞术检测各组细胞凋亡情况，Rhodamine123法检测各组绿色荧光强度及线粒体膜电位，Western blotting法检测各组HER2表达水平。结果　LAP的IC50为1.65 μmol/L，选取1.00 μmol/L（LAP组细胞的生长抑制率为40.12%）为后续研究LAP组、LAP+PDT组给药浓度。5-ALA的IC50为1.57 mmol/L，选取1.00 mmol/L（PDT组细胞的生长抑制率为41.23%）为后续研究PDT组、LAP+PDT组给药浓度。当LAP为1.00 mmol/L，5-ALA为1.00 μmol/L时，LAP+PDT组细胞生长抑瘤率为79.71%。联合治疗Q≈1.23。LAP组、PDT组、LAP+PDT组24、48 h细胞生长抑制率均大于空白对照组（P<0.05）；PDT组48 h细胞生长抑制率大于LAP组（P<0.05）；LAP+PDT组24、48 h细胞生长抑制率均大于LAP组、PDT组（P<0.05）。与空白对照组相比，LAP组、PDT组的细胞主要表现为凋亡，LAP+PDT组则出现了明显的凋亡和坏死，早期凋亡占比很低。LAP组、PDT组荧光强度有所降低；LAP+PDT组的荧光强度降低最明显。LAP组、PDT组、LAP+PDT组线粒体膜电位低于空白对照组（P<0.05）；PDT组、LAP+PDT组线粒体膜电位低于LAP组（P<0.05）；LAP+PDT组线粒体膜电位低于PDT组（P<0.05）。LAP组、PDT组、LAP+PDT组HER2表达水平均低于空白对照组（P<0.05）；PDT组、LAP+PDT组HER2表达水平均低于LAP组（P<0.05）；LAP+PDT组HER2表达水平均低于PDT组（P<0.05）。结论　新型光敏剂5-ALA用于PDT对HER2阳性乳腺癌细胞系SKBR3具有明显的抑制作用，且PDT联合LAP的抑制作用更强，其机制与降低肿瘤细胞线粒体膜电位、HER2表达水平有一定关系。因此，PDT联合LAP有望改善HER2阳性乳腺癌患者生活质量，提高其生存率，具有良好的应用前景。

关键词: 乳腺肿瘤；光化学疗法；拉帕替尼；受体, 表皮生长因子

Abstract: Background　Photodynamic therapy（PDT）has a good therapeutic effect on proliferative diseases，and it shows high efficiency and small toxic and side effects in anti-tumor treatment.Lapatinib（LAP）is an oral tablet，which mainly acts on human epidermal growth factor receptor 1 and 2（HER1 and HER2），and belongs to double-targeted receptor tyrosine kinase inhibitors.However，the synergistic effect of PDT and LAP is still not clear.Objective　To investigate the inhibitory effect and mechanism of PDT with a novel photosensitizer，5-aminolaevulinic acid（5-ALA）on HER2 positive breast cancer cells SKBR3，and to discuss the therapeutic effect of PDT with LAP on HER2-positive breast cancer，providing evidence for the treatment and research of HER2 positive breast cancer.Methods　This study was conducted from May 2016 to December 2017.SKBR3 cells were randomly divided into blank control group（without intervention），LAP group〔intervened with LAP of different concentration gradients（0.50，1.00，2.00，5.00，10.00 μmol/L）〕and PDT group〔first intervened with 5-ALA of different concentration gradients（0.25，0.50，1.00，2.00，4.00 mmol/L），then were exposed to laser〕，LAP+PDT group〔first intervened with different concentration gradients of LAP（0.50，1.00，2.00，5.00，10.00 μmol/L），then with different concentration gradients of 5-ALA（0.25，0.50，1.00，2.00，4.00 mmol/L），and later were exposed to laser〕，respectively.Half maximal inhibitory concentration（IC50）of LAP and 5-ALA was calculated，respectively，and their optimal concentrations for LAP，PDT and LAP+PDT subgroups were determined.Cell growth inhibition rates in each group at 24，48 hours after intervention with the optimal concentration were estimated and compared.SKBR3 cells in the log-phase of growth were randomly divided into blank control group（without intervention），LAP group（intervened with 1.00 μmol/L LAP），PDT group（intervened with 1.00 mmol/L 5-ALA，followed by laser irradiation），LAP+PDT group（intervened with 1.00 μmol/L LAP，then 1.00 mmol/L 5-ALA，followed by laser irradiation）．Flow cytometry was used to detect the apoptotic status of each group.In addition，fluorescence intensity of green fluorescent protein and mitochondrial membrane potential were detected by Rhodamine 123，and the expression of HER2 was detected by Western blotting.Results　The IC50 of LAP was 1.65 μmol/L，and 1.00 μmol/L（the growth inhibition rate of LAP group was 40.12%）was chosen as the administration concentration of LAP and LAP+PDT groups.The IC50 of 5-ALA was 1.57 mmol/L.The administration concentration of 5-ALA in PDT and LAP+PDT groups was determined as 1.00 mmol/L（the growth inhibition rate of PDT group was 41.23%）．When LAP was 1.00 mmol/L and 5-ALA was 1.00 μmol/L，the growth inhibition rate of LAP+PDT group was 79.71%.Combined treatment Q≈1.23.The growth inhibition rates of LAP，PDT and LAP+PDT groups at 24 and 48 hours were higher than those of blank control group（P<0.05）；the growth inhibition rates of PDT group at 48 hours were higher than those of LAP group（P<0.05）；the growth inhibition rates of LAP+PDT group at 24 and 48 hours were higher than those of LAP group and PDT group（P<0.05）．Compared with the blank control group，the cells in LAP and PDT groups mainly manifested as apoptosis，while those in LAP + PDT group showed obvious apoptosis and necrosis，and the proportion of early apoptosis was very low.The fluorescence intensity of green fluorescent protein in LAP and PDT groups decreased，and that of LAP + PDT group decreased most obviously.Mitochondrial membrane potential in LAP，PDT and LAP + PDT groups was lower than that in blank control group（P<0.05）；mitochondrial membrane potential in PDT group and LAP + PDT group was lower than that in LAP group（P<0.05）；mitochondrial membrane potential in LAP + PDT group was lower than that in PDT group（P<0.05）．The expression of HER2 in blank control group was higher than that of other groups（P<0.05），and it in LAP group was higher than that of PDT and LAP + PDT groups，too（P<0.05），and similar status was found when compared HER2 in PDT group with that of LAP + PDT group（P<0.05）．Conclusion　5-ALA had obvious inhibitory effect on SKBR3 cells，and the inhibitory effect became stronger when PDT was used in combination with LAP.The mechanism is related to the reduction of mitochondrial membrane potential and the expression of HER2 in cancer cells.Therefore，PDT combined with LAP is expected to improve the quality of life and survival rate of HER2-positive breast cancer patients，and has a good application prospect.

Key words: Breast neoplasms；Photochemotherapy；Lapatinib；Receptor, epidermal growth factor

孙蓓,张丽,刘晓东,等. 光动力疗法联合拉帕替尼抑制人表皮生长因子受体-2阳性乳腺癌细胞的基础研究[J]. 中国全科医学, 2019, 22(21): 2551-2556. DOI: 10.12114/j.issn.1007-9572.2019.00.165.
SUN Bei,ZHANG Li,LIU Xiaodong, et al. Effect of 5-ALA Mediated Photodynamic Therapy Combined with Lapatinib on Breast Cancer Cell：a Potential Strategy to Improve HER2-positive Breast Cancer Therapeutic Efficacy　[J]. Chinese General Practice, 2019, 22(21): 2551-2556. DOI: 10.12114/j.issn.1007-9572.2019.00.165.

参考文献

［1］BLANCHETTE P S，DESAUTELS D N，POND G R，et al．Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab［J］．Breast Cancer Res Treat，2018，170（1）：169-177．DOI：10.1007/s10549-018-4734-x.
［2］LEE K H，KIM E Y，YUN J S，et al．Prognostic significance of expression of epithelial-mesenchymal transition driver brachyury in breast cancer and its association with subtype and characteristics［J］．Oncol Lett，2018，15（1）：1037-1045．DOI：10.3892/ol.2017.7402.
［3］XU T，HE B S，LIU X X，et al．The predictive and prognostic role of stromal tumor-infiltrating lymphocytes in HER2-positive breast cancer with trastuzumab-based treatment：a meta-analysis and systematic review［J］．J Cancer，2017，8（18）：3838-3848．DOI：10.7150/jca.21051.
［4］DOBSON J，DE QUEIROZ G F，GOLDING J P.Photodynamic therapy and diagnosis：principles and comparative aspects［J］．Vet J，2018，233：8-18．DOI：10.1016/j.tvjl.2017.11.012.
［5］NOH I，LEE D，KIM H，et al．Enhanced photodynamic cancer treatment by mitochondria-targeting and brominated near-infrared fluorophores［J］．Adv Sci（Weinh），2017，5（3）：1700481．DOI：10.1002/advs.201700481.
［6］TANEJA S S.Re：padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer（CLIN1001 PCM301）：an open-label，phase3，randomised controlled trial［J］．J Urol，2017，198（2）：255-257．DOI：10.1016/j.juro.2017.05.029.
［7］NIELSEN S M，WHITE M G，HONG S，et al．The breast-thyroid cancer link：a systematic review and meta-analysis［J］．Cancer Epidemiol Biomarkers Prev，2016，25（2）：231-238．DOI：10.1158/1055-9965.EPI-15-0833.
［8］CHEN W，ZHENG R，ZENG H，et al．The updated incidences and mortalities of major cancers in China，2011［J］．Chin J Cancer，2015，34（11）：502-507．DOI：10.1186/s40880-015-0042-6.
［9］MARTA G N，HIJAL T，DE ANDRADE CARVALHO H.Reirradiation for locally recurrent breast cancer［J］．Breast，2017，33：159-165．DOI：10.1016/j.breast.2017.03.008.
［10］ALLISON R，MANG T，HEWSON G，et al．Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality［J］．Cancer，2001，91（1）：1-8.
［11］顾瑛，丁新民，刘凡光，等．不同活性氧成分在血卟啉单甲醚-PDT诱导HeLa细胞死亡中的作用［J］．中国激光医学杂志，2003，12（4）：217-220．DOI：10.3969/j.issn.1003-9430.2003.04.004.
GU Y，DING X M，LIU F G，et al．Effect of different reactive oxygen species on HeLa cells death mediated by HMME-PDT［J］．Chinese Journal of Laser Medicine & Surgery，2003，12（4）：217-220．DOI：10.3969/j.issn.1003-9430.2003.04.004.
［12］MIMIKOS C，SHAFIRSTEIN G，ARSHAD H.Current state and future of photodynamic therapy for the treatment of head and neck squamous cell carcinoma［J］．World J Otorhinolaryngol Head Neck Surg，2016，2（2）：126-129．DOI：10.1016/j.wjorl.2016.05.011.
［13］MüLLER V，CLEMENS M，JASSEM J，et al．Long-term trastuzumab（Herceptin?）treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer［J］．BMC Cancer，2018，18（1）：295．DOI：10.1186/s12885-018-4183-2.
［14］LABIDI S，MEJRI N，LAGHA A，et al．Targeted therapies in HER2-overexpressing metastatic breast cancer［J］．Breast Care（Basel），2016，11（6）：418-422．DOI：10.1159/000452194.
［15］KHDAIR A，HANDA H，MAO G，et al．Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro［J］．Eur J Pharm Biopharm，2009，71（2）：214-222．DOI：10.1016/j.ejpb.2008.08.017.
［16］CANTI G，NICOLIN A，CUBEDDU R，et al．Antitumor efficacy of the combination of photodynamic therapy and chemotherapy in murine tumors［J］．Cancer Lett，1998，125（1/2）：39-44.
［17］PAL R，ANSARI M A，SAIBABU V，et al．Nonphotodynamic roles of methylene blue：display of distinct antimycobacterial and anticandidal mode of actions［J］．J Pathog，2018，2018：3759704．DOI：10.1155/2018/3759704.
［18］HOSSEINZADEH R，KHORSANDI K，JAHANSHIRI M.Combination photodynamic therapy of human breast cancer using salicylic acid and methylene blue［J］．Spectrochim Acta A Mol Biomol Spectrosc，2017，184：198-203．DOI：10.1016/j.saa.2017.05.008.
ZHOU C L，LIU Y，LUO X R.Reliability and validity of Patient Health Questionnaire in Inpatients with Diabetic Foot Ulcers［J］．Chinese General Practice，2016，19（28）：3461-3466．DOI：10.3969/j.issn.1007-9572.2016.28.016.
［9］张明园.精神科评定量表手册［M］．2版.长沙：湖南科学技术出版社，1998.
［10］杨坤，胡义秋，崔景秋，等．糖尿病抑郁综合征的研究进展［J］．国际精神病学杂志，2015，42（1）：90-94.
YANG K，HU Y Q，CUI J Q，et al．Research progress of diabetic depression syndrome［J］．Journal of International Psychiatry，2015，42（1）：90-94.
［11］LLOYD C E，SARTORIUS N，CIMINO L C，et al．The INTERPRET-DD study of diabetes and depression：a protocol［J］．Diabet Med，2015，32（7）：925-934．DOI：10.1111/dme.12719.
［12］LEONE T，COAST E，NARAYANAN S，et al．Diabetes and depression comorbidity and socio-economic status in low and middle income countries （LMICs）：a mapping of the evidence［J］．Global Health，2012，8：39-49．DOI：10.1186/1744-8603-8-39.
［13］许敏，邓大同，王佑民.糖尿病与抑郁症［J］．安徽医药，2011，15（5）：631-634．DOI：10.3969/j.issn.1009-6469.2011.05.049.
XU M，DENG D T，WANG Y M.Diabetes and depression［J］．Anhui Medical and Pharmaceutical Journal，2011，15（5）：631-634．DOI：10.3969/j.issn.1009-6469.2011.05.049.
［14］DEMMER R T，GELB S，SUGLIA S F.Sex differences in the association between depression，anxiety，and type 2 diabetes mellitus［J］．Psychosom Med，2015，77（4）：467-477．DOI：10.1097/PSY.0000000000000169.
［15］黄海珊，汪晖，李玲，等．住院患者心理应激反应及影响因素关系的模型构建［J］．护理学杂志，2009，24（19）：1-4．DOI：10.3870/hlxzz.2009.19.001.
HUANG H S，WANG H，LI L，et al．Construction of a model for the psychological stress response and its influencing factors of inpatients［J］．Journal of Nursing Science，2009，24（19）：1-4．DOI：10.3870/hlxzz.2009.19.001.
［16］PAWLOWSKA B，OPOLSKA A，PAPUC E，et al．Present and premorbid self-image in patients with coronary heart disease［J］．Psychiatr Pol，2006，40（2）：311-322.

[1]	郭紫薇，梁莉. 表皮生长因子受体野生型晚期非小细胞肺癌治疗的选择[J]. 中国全科医学, 2015, 18(6): 707-710.
[2]	张昊，尹璇，陈建平，马莉，张春江，刘春. 活性维生素D3对人系膜细胞凋亡及Caspase-3表达的影响[J]. 中国全科医学, 2015, 18(5): 540-543.